Management of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Multiple-Day Highly or Moderately Emetogenic Chemotherapy: Role of Transdermal Granisetron

References

• Hesketh PJ , BohlkeK, LymanGHet al. Antiemetics: American Society of Clinical Oncology focused guideline update. J. Clin. Oncol.34(4), 381–386 (2016).
   PubMed Web of Science ®Google Scholar
• Kris MG , TonatoM, BriaEet al. Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer19(Suppl. 1), S25–S32 (2011).
   PubMedGoogle Scholar
• Graybiel A . Coping with space motion sickness in Spacelab missions. Acta Astronaut.8(9–10), 1015–1018 (1981).
   PubMed Web of Science ®Google Scholar
• Casale R , PolatiE, SchweigerV, ColuzziF, BhaskarA, ConsalvoM. [Localized neuropathic pain – 5% lidocaine medicated patch as a first-line treatment and as add-on therapy: literature review and personal experience]. Minerva Med.105(3), 177–195 (2014).
   PubMed Web of Science ®Google Scholar
• Kraut L , FauserAA. Anti-emetics for cancer chemotherapy-induced emesis: potential of alternative delivery systems. Drugs61(11), 1553–1562 (2001).
   PubMed Web of Science ®Google Scholar
• Duggan ST , CurranMP. Transdermal granisetron. Drugs69(18), 2597–2605 (2009).
   PubMed Web of Science ®Google Scholar
• Coluzzi F , RoccoA, MandatoriI, MattiaC. Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation. Curr. Pharm. Des.18(37), 6043–6052 (2012).
   PubMed Web of Science ®Google Scholar
• Howell J , SmeetsJ, DrenthHJ, GillD. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J. Oncol. Pharm. Pract.15(4), 223–231 (2009).
   PubMedGoogle Scholar
• Haislip ST , GilmoreJW, HowellJD. Results from four pharmacokinetic studies of the granisetron transdermal system. Res. Rep. Transderm. Drug Deliv.2013(2), 19–26 (2013).
   Google Scholar
• European Medicines Agency . EMA Public Assessment Report Sancuso® 16 February 2012 EMA/228344/2012. Committee for Medicinal Products for Human Use (CHMP). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002296/WC500127130.pdf.
   Google Scholar
• Tuca A . Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review. Cancer Manag. Res.2, 1–12 (2010).
   Google Scholar
• Keating GM , DugganST, CurranMP. Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy. CNS Drugs26(9), 787–790 (2012).
   PubMed Web of Science ®Google Scholar
• Howell J , ClarkG, YellowleesA, Gutierrez-EsteinouR. Efficacy, safety, and tolerability of a transdermal granisetron patch for prevention of single-dose chemotherapy-induced nausea and vomiting: Phase II trial results. J. Oncol. Pharm. Pract.15(Suppl. 2), 20 (2009).
   Google Scholar
• Straken Pharmeceutical Ltd . Clinical Study Report 392MD/8/C, May 2007.
   Google Scholar
• Aapro M , FabiA, NolèFet al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann. Oncol.21(5), 1083–1088 (2010).
   PubMed Web of Science ®Google Scholar
• Celio L , FrustaciS, DenaroAet al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, Phase III trial. Support Care Cancer19(8), 1217–1225 (2011).
   PubMed Web of Science ®Google Scholar
• Komatsu Y , OkitaK, YukiSet al. Open-label, randomized, comparative, Phase III study on effects of reducing steroid use in combination with palonosetron. Cancer Sci.106(7), 891–895 (2015).
   PubMed Web of Science ®Google Scholar
• MASCC/ESMO antiemetic guideline 2016. www.mascc.org/assets/Guidelines-Tools/mascc_antiemetic_guidelines_english_2016_v.1.1.pdf.
   Google Scholar
• Boccia RV , GordanLN, ClarkG, HowellJD, GrunbergSM. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, Phase III study. Support Care Cancer19(10), 1609–1617 (2011).
   PubMed Web of Science ®Google Scholar
• Kim JE , HongYS, LeeJLet al. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. Support Care Cancer23(6), 1769–1777 (2015).
   PubMed Web of Science ®Google Scholar
• Boccia RV , ClarkG, HowellJD. Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy. Cancer Manag. Res.4, 171–176 (2012).
   PubMedGoogle Scholar
• Hesketh PJ , KrisMG, GrunbergSMet al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol.15(1), 103–109 (1997).
   PubMed Web of Science ®Google Scholar
• Seol YM , KimHJ, ChoiYJet al. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and Phase IV study. Support Care Cancer24(2), 945–952 (2015).
   PubMed Web of Science ®Google Scholar
• Dunnington H , HunterR, FrumovitzM, SmithJ. Granisetron transdermal patch for treatment of nausea in patients undergoing cisplatin based chemotherapy for cervical cancer. J. Cancer Ther.3, 1159–1163 (2012).
   Google Scholar
• Kirwan JM , SymondsP, GreenJA, TierneyJ, CollingwoodM, WilliamsCJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother. Oncol.68(3), 217–226 (2003).
   PubMed Web of Science ®Google Scholar
• Coluzzi F , BertiM. Change Pain: changing the approach to chronic pain. Minerva Med.102(4), 289–307 (2011).
   PubMed Web of Science ®Google Scholar
• Brygger L , HerrstedtJ. 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin. Drug Saf.13(10), 1407–1422 (2014).
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation (ICH) . Guidance for industry: E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073153.pdf.
   Google Scholar
• Mason JW , MoonTE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag. Res.5, 179–185 (2013).
   PubMedGoogle Scholar
• Drug safety communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). Silver Spring, MD, USA: US FDA (2010). www.fda.gov/Drugs/DrugSafety/ucm237081.htm#safety_announcement.
   Google Scholar
• Sanofi-Aventis . ANZEMET (dolasetron mesylate) – withdrawal of 20 mg/mL intravenous injection due to potential risk of arrhythmias – for health professionals. Health Canada endorsed important safety information on ANZEMET intravenous injection. www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/14633a-eng.php.
   Google Scholar
• Freedman SB , UlerykE, RumantirM, FinkelsteinY. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann. Emerg. Med.64(1), 19–25.e16 (2014).
   PubMed Web of Science ®Google Scholar
• Drug safety communication: New information regarding QT prolongation with ondansetron (Zofran) Silver Spring, MD, USA: US FDA, 29 June 2012. www.fda.gov/Drugs/DrugSafety/ucm310190.htm.
   Google Scholar
• Gonullu G , DemircanS, DemiragMK, ErdemD, YucelI. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer20(7), 1435–1439 (2012).
   PubMed Web of Science ®Google Scholar
• Kim HJ , LeeHC, JungYSet al. Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia. Br. J. Anaesth.112(3), 460–468 (2014).
   PubMed Web of Science ®Google Scholar
• Kytril (granisetron hydrochloride) tablets [package insert]. Nutley, NJ, USA: Roche Laboratories Inc. (2010). http://www.drugs.com/pro/kytril.html.
   Google Scholar
• Patel DR , JoshiA, PatelHH, StagniG. Development and in-vivo evaluation of ondansetron gels for transdermal delivery. Drug Dev. Ind. Pharm.41(6), 1030–1036 (2015).
   PubMed Web of Science ®Google Scholar
• Woodall R , ArnoldJJ, MckayD, AsbillCS. Effect of formulation pH on transdermal penetration of antiemetics formulated in poloxamer lecithin organogel. Int. J. Pharm. Compd.17(3), 247–253 (2013).
   PubMedGoogle Scholar
• Kamen C , TejaniMA, ChandwaniKet al. Anticipatory nausea and vomiting due to chemotherapy. Eur. J. Pharmacol.722, 172–179 (2014).
   PubMed Web of Science ®Google Scholar
• Simmons K , ParkmanHP. Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis. Dig. Dis. Sci.59(6), 1231–1234 (2014).
   PubMed Web of Science ®Google Scholar
• Caritis S , ZhaoY, ChenHJ, VenkataramananR. Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy. Am. J. Obstet. Gynecol. doi: 10.1016/j.ajog.2016.01.163 (2016) ( Epub ahead of print).
   Google Scholar